Illumina will acquire Pacific Biosciences for $1.2 billion, it was revealed on Friday, after the agreement had been approved by the board of directors of Illumina and Pacific Biosciences.
Denali, Sanofi together developing RIPK1 inhibitors for treating neurological and inflammatory diseases
Denali Therapeutics will work with Sanofi on its multiple RIPK1 inhibitor molecules that could treat a range of neurological and systemic inflammatory diseases.
Omya, a producer of industrial minerals informed Monday about a price increase of 7 – 9% for its Calcium Carbonate products in the US and Canada, from the start of the next year.
@n4pharma with MedImmune UK, has been studying the level of immune response Nuvec can deliver when combined with a target antigen in a study using messenger RNA (mRNA) and plasmid DNA (pDNA) encoded with the standard test antigen Ovalbumin (OVA).
Spanish contract development and manufacturing organisation (CDMO) @Idifarma has begun its seventh project with Spanish biotechnology company, Palobiofarma.
LEH Pharma, a provider of revolutionary ocular implants for macular disorders, has picked Syneos Health, a fully integrated biopharmaceutical solutions organization, as its Global Clinical Development and Commercialisation Provider.
Hemogenyx and Orgenesis have entered into collaboration on the further development of Human Postnatal Hemogenic Endothelial Cell technology
Foamix Pharmaceuticals showed its topline results of its third Phase 3 clinical trial (FX2017-22) of FMX101 for the treatment of moderate-to-severe acne.
PureTech Health and its affiliate Karuna have completed a $42 million Series A financing round, which will be used to
Amryt ensure US Food and Drug Administration’s grant a Rare Pediatric Disease designation for its lead development asset AP101, for